Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Victrelis' final European approval means that Merck & Co. has its nose in front of rival Vertex for the time being.
You may also be interested in...
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle
Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.
J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle
Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.